

Shahin Sanjar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7880920/publications.pdf>

Version: 2024-02-01

12
papers

40
citations

1936888

4
h-index

1872312

6
g-index

14
all docs

14
docs citations

14
times ranked

46
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies. <i>Respiratory Research</i> , 2019, 20, 135.	1.4	8
2	Effect of background long-acting beta ₂ -agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 2917-2929.	0.9	7
3	Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate. <i>International Journal of COPD</i> , 2020, Volume 15, 995-1004.	0.9	5
4	Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4. <i>International Journal of COPD</i> , 2018, Volume 14, 27-37.	0.9	4
5	Efficacy and Safety of Nebulized Glycopyrrolate/eFlow® Closed System in Patients with Moderate-to-Very-Severe Chronic Obstructive Pulmonary Disease with Pre-Existing Cardiovascular Risk Factors. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019, 6, 86-99.	0.5	4
6	Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies. <i>International Journal of COPD</i> , 2021, Volume 16, 865-875.	0.9	4
7	Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of the GEM1 and GEM2 12-week studies. <i>International Journal of COPD</i> , 2019, Volume 14, 461-470.	0.9	2
8	Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD. <i>International Journal of COPD</i> , 2021, Volume 16, 1061-1073.	0.9	2
9	The Effect of Metabolic Syndrome Status on Lung Function and Patient-reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020, 7, 315-326.	0.5	2
10	The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies. <i>International Journal of COPD</i> , 2020, Volume 15, 745-754.	0.9	1
11	Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate. <i>International Journal of COPD</i> , 2021, Volume 16, 945-955.	0.9	1
12	Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD. <i>Npj Primary Care Respiratory Medicine</i> , 2021, 31, 43.	1.1	0